[Partial regression of a desmoid tumor after prolonged treatment with lanreotide].
Mannant
P R
PR
Beau
P
P
De Lédinghen
V
V
Barrioz
T
T
Genestin
E
E
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018222:Desmoid Tumors / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007414:Intestinal Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy*; D008297:Male; D008643:Mesentery / Q000473:pathology*; D010288:Parenteral Nutrition; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin
Régression partielle d'une tumeur desmoïde après traitement prolongé par le lanréotide.